# IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

> **NCT07674615** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Gynecologic Oncology Group** · enrollment: 19 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancers
- Primary
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan monotherapy

## Key facts

- **NCT ID:** NCT07674615
- **Lead sponsor:** Shanghai Gynecologic Oncology Group
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674615, "IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*